EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Validation of a Mucosal IgA Assay for SARS-CoV-2

Mingzhu Zhu iD, Edmond Massuda, Shane Cloney-Clark, Urvashi Patel iD, Anand Parekh, Andrew Gorinson, Andrew Klindworth, Ali Ahmadi, Miranda R Cai, Chijioke Bennett, Raj Kalkeri, Joyce S Plested

Microorganisms · 20.05.2026 · 14 (5) · 1154

DOI: 10.3390/microorganisms14051154 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microorganisms, online erschienen am 20.05.2026. Verfasst von Mingzhu Zhu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Immunology, Novavax, Gaithersburg, MD 20878, USA. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novavax (United States), Novavax, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mucosal immunity, including antibodies like immunoglobulin A (IgA), function as the body’s first line of defense in the respiratory tract, particularly against viruses. An anti-rS protein IgA enzyme-linked immunosorbent assay (ELISA) was developed using the Omicron XBB.1.5 subvariant of SARS-CoV-2 and was validated to demonstrate the suitability of the method for testing saliva from SARS-CoV-2 vaccine clinical trials. This assay successfully met acceptance criteria for inter-/intra-assay precision, specificity, selectivity, linearity, lower/upper limits of quantitation, and assay robustness. The IgA in saliva was stable for up to 7 freeze/thaw cycles, for up to 48 h at 24 °C, up to 7 days at 4 °C, up to 3 weeks at −20 °C, and up to 1 year at −80 °C. After validation using Omicron XBB.1.5 rS protein, cross-reactivity was demonstrated with the SARS-CoV-2 variant JN.1. This validated IgA assay can be a valuable tool to assess mucosal IgA levels in SARS-CoV-2 clinical trials.

Schlagwörter

Stichwörter der Autor:innen

COVID-19Omicron XBB.1.5SARS-CoV-2assay validationcorrelate of protectionimmunogenicity

Autor:innen und Institutionen

  • Clinical Immunology, Novavax, Gaithersburg, MD 20878, USA.
  • Biostatistics, Novavax, Gaithersburg, MD 20878, USA.
  • Clinical Development, Novavax, Gaithersburg, MD 20878, USA.

ORCID-Profile: Mingzhu Zhu, Urvashi Patel

Förderung

  • Novavax (United States)
  • Novavax, Inc.

Zitieren

APA

Zhu, M., Massuda, E., Cloney-Clark, S., Patel, U., Parekh, A., Gorinson, A., Klindworth, A., Ahmadi, A., Cai, M. R., Bennett, C., Kalkeri, R., & Plested, J. S. (2026). Validation of a Mucosal IgA Assay for SARS-CoV-2. Microorganisms, 14(5), 1154. https://doi.org/10.3390/microorganisms14051154

Vancouver

Zhu M, Massuda E, Cloney-Clark S, Patel U, Parekh A, Gorinson A, et al. Validation of a Mucosal IgA Assay for SARS-CoV-2. Microorganisms. 2026;14(5):1154. doi:10.3390/microorganisms14051154

BibTeX
@article{Zhu2026,
  author = {Zhu, Mingzhu and Massuda, Edmond and Cloney-Clark, Shane and Patel, Urvashi and Parekh, Anand and Gorinson, Andrew and Klindworth, Andrew and Ahmadi, Ali and Cai, Miranda R and Bennett, Chijioke and Kalkeri, Raj and Plested, Joyce S},
  title = {Validation of a Mucosal IgA Assay for SARS-CoV-2},
  journal = {Microorganisms},
  year = {2026},
  volume = {14},
  number = {5},
  pages = {1154},
  doi = {10.3390/microorganisms14051154}
}
Kostenlos starten →